Abstract
Treatment options are limited for patients with recurrent and/or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC); mortality rates exceed 70% in patients with distant metastases. Here, we present the first interim analysis of the R/M cSCC cohort from the 2-cohort-locally advanced and R/M-phase II KEYNOTE-629 study. Patients with R/M cSCC not amenable to surgery or radiation received pembrolizumab 200 mg every 3 weeks. The primary end point was objective response rate per RECIST v1.1. Secondary end points were duration of response, disease control rate, progression-free survival, overall survival, and safety. At data cutoff (April 8, 2019), median follow-up of 105 enrolled patients in the R/M cohort was 11.4 months (range, 0.4 to 16.3 months). Objective response rate was 34.3% (95% CI, 25.3% to 44.2%; 4 complete responses, 32 partial responses), and disease control rate was 52.4% (95% CI, 42.4% to 62.2%). Median duration of response was not reached (range, 2.7 to 13.1+ months; '+' refers to ongoing response at data cutoff). Median progression-free survival was 6.9 months (95% CI, 3.1 months to 8.5 months). Median overall survival was not reached (95% CI, 10.7 months to not reached). Treatment-related adverse events occu...Continue Reading
References
Apr 15, 1991·Cancer·T Khansur, A Kennedy
Apr 15, 1985·Cancer·T H GuthrieJ D Harmon
May 4, 2005·The Laryngoscope·Michael J VenessVal Gebski
May 2, 2006·Cancer·Michael J VenessGary J Morgan
Feb 23, 2010·Lancet·Vishal MadanRolf-Markus Szeimies
Aug 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eve MaubecMarie-Françoise Avril
Jan 24, 2012·Head & Neck·Markus BrunnerJonathan R Clark
May 18, 2012·Journal of Surgical Oncology·Nicholas D L S BroughamSwee T Tan
May 17, 2013·JAMA Dermatology·Chrysalyne D SchmultsAbrar A Qureshi
Feb 25, 2014·The British Journal of Oral & Maxillofacial Surgery·Ben Gurney, Carrie Newlands
Aug 6, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M C FooteS V Porceddu
Oct 12, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Curtis R PickeringMitchell J Frederick
Feb 3, 2015·Genes & Diseases·Young Kim, Yu-Ying He
May 1, 2015·JAMA Dermatology·Howard W RogersBrett M Coldiron
Jul 30, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alexander StratigosUNKNOWN European Organization for Research and Treatment of Cancer (EORTC)
Jan 15, 2016·JAMA Dermatology·Agnieszka K ThompsonChristian L Baum
Apr 20, 2016·The New England Journal of Medicine·Paul T NghiemMartin A Cheever
May 7, 2016·Journal of Cutaneous Pathology·Nathaniel A Slater, Paul B Googe
Jul 1, 2016·American Journal of Clinical Dermatology·Kyle A BurtonAmor Khachemoune
Mar 23, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joshua BaumlRobert Haddad
Dec 21, 2017·The New England Journal of Medicine·Mark YarchoanElizabeth M Jaffee
Jun 5, 2018·The New England Journal of Medicine·Michael R MigdenMatthew G Fury
Jun 30, 2018·British Journal of Cancer·Ranee MehraRobert Haddad
Dec 5, 2018·Lancet·Ezra E W CohenUNKNOWN KEYNOTE-040 investigators
Citations
Sep 12, 2020·Cancers·Marianna GarofoliAmalia Azzariti
Feb 9, 2021·Expert Review of Anticancer Therapy·Eve LebasArjen F Nikkels
Dec 10, 2020·International Journal of Molecular Sciences·Anja WesselyMarkus Vincent Heppt
Feb 16, 2021·Otolaryngologic Clinics of North America·Caitlin P McMullen, Thomas J Ow
Feb 20, 2021·Otolaryngologic Clinics of North America·Karen Y Choi, Cecelia E Schmalbach
Mar 17, 2021·Current Treatment Options in Oncology·Enrico ZelinClaudio Conforti
Jan 22, 2021·Journal of the American Academy of Dermatology·Sophia Z ShalhoutDavid M Miller
Sep 28, 2020·Ophthalmology·Hakan DemirciFrancis Worden
Apr 4, 2021·Cancers·Yosuke IshitsukaManabu Fujimoto
May 4, 2021·Frontiers in Oncology·Annette M LimDanny Rischin
Jun 8, 2021·Current Treatment Options in Oncology·Priyanka ReddyMonaliben Patel
Jun 9, 2021·Journal of Immunotherapy·Sophia Z ShalhoutDavid M Miller
Jun 14, 2021·Radiation Oncology·Erik HaehlNils H Nicolay
Jul 2, 2021·Annals of Surgical Oncology·Flora YanAndrew T Day
Jul 25, 2021·Cancers·Candice HoberÈve Maubec
Jul 27, 2021·Frontiers in Pharmacology·Yating ZhaoLiang Weng
Jul 23, 2021·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B G M HughesJ-J Grob
Jul 10, 2021·Advances in Therapy·Renata FerrarottoAung Naing
Aug 6, 2021·Journal of Managed Care & Specialty Pharmacy·Eleanor PaulAndreas Kuznik
Jul 1, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Renata FerrarottoNeil D Gross
Aug 21, 2021·Journal for Immunotherapy of Cancer·Danny RischinMichael R Migden
Aug 28, 2021·Current Oncology Reports·Sophia Z ShalhoutDavid M Miller
Dec 4, 2020·Annales de dermatologie et de vénéréologie·H Montaudié
Sep 25, 2021·Dermatology and Therapy·Brett G M HughesJean-Jacques Grob
Oct 15, 2021·Cancer Imaging : the Official Publication of the International Cancer Imaging Society·Luke S McLeanDanny Rischin
Oct 16, 2021·Advances in Therapy·Kylee J B Kus, Emily S Ruiz
Oct 27, 2021·The Australasian Journal of Dermatology·Nader Aboul-FettouhMichael Migden
Nov 3, 2021·Journal for Immunotherapy of Cancer·Shubham PantAung Naing
Oct 30, 2021·Journal of the American Academy of Dermatology·Takuya MaedaKoji Yoshino